Literature DB >> 8394449

Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2.

J M Martin1, D Veis, S J Korsmeyer, B Sugden.   

Abstract

The stable expression of the Epstein-Barr virus (EBV) latent membrane protein (LMP) in certain EBV-negative Burkitt's lymphoma cell lines correlates with an increased expression of the oncogene Bcl-2 (S. Henderson, M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff, and A. Rickinson, Cell 65:1107-1115, 1991). This finding is consistent with a model in which Bcl-2 contributes to the immortalization of B cells mediated by EBV. We therefore asked whether the expression of Bcl-2 protein correlates with the induction of three cellular phenotypes induced by or associated with LMP. The expression of Bcl-2 in primary B cells infected with the B95-8 strain of EBV varied between 1 and 1.8 times that in uninfected cells when 50% of the cells were infected, expressed LMP, and incorporated 20-fold more [3H]thymidine than did uninfected cells. This finding indicates that induced proliferation of these primary cells is not sufficient to induce Bcl-2. We found that BALB/c 3T3 cells and their derivatives transformed by LMP do not express Bcl-2 detectably. The expression of LMP at high levels in lymphoid cells is cytotoxic and correlates with an increased expression of Bcl-2 following stable selection for the introduced LMP gene; 2 days after transfection, control vector- and LMP-transfected populations, however, express equal levels of Bcl-2 protein. We also analyzed transient expression of LMP in an EBV-negative Burkitt's lymphoma cell line. Infection of BJAB cells with the B95-8 strain of EBV results in an increase in Bcl-2 expression with a time course similar to that of LMP expression, and LMP alone transiently induces an increase in Bcl-2 expression in these cells. We interpret these observations to indicate that increased expression of Bcl-2 is unlikely to contribute to the ability of EBV to immortalize primary B cells and that both the transformation of rodent cells and the cytotoxicity mediated by LMP are independent of Bcl-2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394449      PMCID: PMC237925     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells.

Authors:  D Liebowitz; J Mannick; K Takada; E Kieff
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  "Panning" for lymphocytes: a method for cell selection.

Authors:  L J Wysocki; V L Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

4.  Development of 3T3-like lines from Balb-c mouse embryo cultures: transformation susceptibility to SV40.

Authors:  S A Aaronson; G J Todaro
Journal:  J Cell Physiol       Date:  1968-10       Impact factor: 6.384

5.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.

Authors:  A Bakhshi; J P Jensen; P Goldman; J J Wright; O W McBride; A L Epstein; S J Korsmeyer
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

6.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.

Authors:  Y Tsujimoto; L R Finger; J Yunis; P C Nowell; C M Croce
Journal:  Science       Date:  1984-11-30       Impact factor: 47.728

7.  Transformation of lymphocytes by Epstein-Barr virus requires only one-fourth of the viral genome.

Authors:  W Mark; B Sugden
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

8.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

Authors:  M L Cleary; J Sklar
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

10.  Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

Authors:  M Rabson; L Heston; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

View more
  27 in total

1.  LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2.

Authors:  A Kieser; C Kaiser; W Hammerschmidt
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.

Authors:  Shunbin Ning; Leslie E Huye; Joseph S Pagano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells.

Authors:  Zachary L Pratt; Jingzhu Zhang; Bill Sugden
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 4.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 5.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

6.  Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.

Authors:  L Waltzer; M Perricaudet; A Sergeant; E Manet
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1.

Authors:  L Zhang; J S Pagano
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

8.  Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1.

Authors:  M Franken; O Devergne; M Rosenzweig; B Annis; E Kieff; F Wang
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus.

Authors:  Christoph Mancao; Markus Altmann; Berit Jungnickel; Wolfgang Hammerschmidt
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

10.  c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.

Authors:  A Polack; K Hörtnagel; A Pajic; B Christoph; B Baier; M Falk; J Mautner; C Geltinger; G W Bornkamm; B Kempkes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.